Beijing QL Biopharmaceutical Co., Ltd.

北京质肽生物医药科技股份有限公司

Biopharmaceutical company developing therapies for obesity and metabolic disorders, including a monthly GLP-1 receptor agonist injection (zovaglutide) in Phase III trials in China, with integrated peptide discovery, clinical development, and GMP manufacturing capabilities.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Overlapping customers and suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Cash burn and runway
• Related-party transactions and balances
• Chapter 18A biotech
• Other